NCT06387771View on ClinicalTrials.gov

Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 22, 2014

Primary Completion Date

August 31, 2025

Conditions
Schizophrenia
Interventions
DRUG

Tolcapone

Tolcapone (Film-coated tablet) 200 mg orally every 8 hours for 7 days

Trial Locations (1)

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

All Listed Sponsors
lead

Clinica Universidad de Navarra, Universidad de Navarra

OTHER

NCT06387771 - Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia | Biotech Hunter | Biotech Hunter